What is the advantage? Genius lies in simplicity

The uniqueness of the plant peptide action is that under the conditions of a decrease in antitumor immunity due to aggressive activity of tumors, or post anticancer chemotherapy, it restores immune surveillance and trigger apoptosis (self-destruction) of cancer cells.

 

On the contrary, i.e. under the conditions of immunocompetent molecule hyperproduction in the case of inflammatory processes, particularly in the liver and kidneys (in hepatitis, cirrhosis, nephritis), plant peptides are capable of reducing the peptide-peptide interaction intensity and prevent unwanted damages and apoptosis of hepatocytes and nephrocytes.

 

How can this be explained? Why do under the conditions of the immune system depression, e.g., in cancer, plant peptides actively join in enhancing the antitumor immunological response, stimulate regulatory lymphocytes, and actively participate in apoptosis of cancer cells? And vice versa, when the immune system is overloaded, inflammatory reactions prevail and there is a danger that vulnerable liver and kidney cells will start to die, why do plant peptides take the side of target organs, protect delicate tissues, and restore their structure and functions?

 

The answer is simple like all genius. Small-sized regulatory proteins act as mediators between the key sections of immune reactions. By filling up the space in a target organ, plant peptides act as adjusters, capturing the slightest signs of imbalance in the immune cascade regulation. They demonstrate their regulatory properties at the level of regulatory proteins inside the cell, in fact, at the level of genes, realizing in this manner the gene protective effect. In case of immune paresis and the need to support immunoactivity, they enhance the immune system.  In the prevalence of inflammation and the risk of vulnerable cellular structures dying, they inhibit inflammatory reactions and protect damaged tissues, creating conditions for the recovery of organ functions. This is how the GA-40 gene protector works.

The history of invention and study of the immunotropic and gene-protective properties of GA-40 is presented in the monograph GA-40. New Immunotherapeutic & Anti-Cancer Drug by Professor Giorgi Alexidze, which was published in 2014 in the United States by Lambert Academic Publishing. Feb 12, 2014.

Moreover, as opposed to other peptide drugs, in particular those animal-based, GA-40 has an unsurpassed safety profile, as it does not contain high weight polypeptides of high antigenic specificity. This is vital in case of the patient’s compromised immune system and lack of any supplementary reserves to neutralize possible allergic reactions and other complications.

 

Over the past decade, more than 100,000 patients worldwide have decided to regain their health and plans for the future with the benefit of the GA-40 peptide immunocorrector. It is also important to note that GA-40 improves the tolerance to chemotherapy, which allows patients to undergo a complete cycle of treatment and in a timely manner. GA-40 has proved its efficacy in the combined treatment of melanoma, cervical cancer, breast cancer, leukemia, and other cancers.

FAQs

The frequently asked questions about GA-40 are presented in this section. Please contact us for close consultation.

Send your message

Let's get in touch

Submitting Form...

The server encountered an error.

Form received

+38 (097) 440 70 37

+38 (097) 697 11 42

Russian language support

contact@regulmedical.com

Please use the chat

+38(097) 440 70 37

©Copyriting by RegulMedical. All rights reserved